株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ラッサ熱:パイプライン製品の分析

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2018

発行 Global Markets Direct 商品コード 363115
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.82円で換算しております。
Back to Top
ラッサ熱:パイプライン製品の分析 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2018
出版日: 2018年09月26日 ページ情報: 英文 55 Pages
概要

当レポートでは、ラッサ熱治療薬の開発状況関する情報を提供しており、開発段階、薬剤標的、作用機序、投与経路および分子タイプ別の分析、治療薬の開発に従事している企業の概要、最新ニュースやプレスリリースなどの情報をお届けします。

イントロダクション

  • 調査範囲

ラッサ熱の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ラッサ熱:企業で開発中の治療薬

ラッサ熱:大学/機関で研究中の治療薬

ラッサ熱:パイプライン製品の概況

  • 初期段階の製品

ラッサ熱:企業で開発中の製品

ラッサ熱:大学/機関で研究中の製品

ラッサ熱の治療薬開発に従事している企業

  • Arno Therapeutics, Inc.
  • Celgene Corporation
  • Etubics Corporation
  • Kineta, Inc.
  • Profectus BioSciences, Inc.
  • SIGA Technologies, Inc.

ラッサ熱:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

ラッサ熱:休止中のプロジェクト

ラッサ熱:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Celgene Corp, H2 2018
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2018
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H2 2018
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, H2 2018
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, H2 2018
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2018
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Themis Bioscience GmbH, H2 2018
  • Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Toyama Chemical Co Ltd, H2 2018
  • Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, H2 2018

List of Figures

  • Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
目次
Product Code: GMDHC10791IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2018, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arena virus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lassa Fever (Lassa Hemorrhagic Fever) - Overview
    • Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development
    • Celgene Corp
    • Etubics Corp
    • GeoVax Labs Inc
    • Inovio Pharmaceuticals Inc
    • Kineta Inc
    • Profectus BioSciences Inc
    • Themis Bioscience GmbH
    • Toyama Chemical Co Ltd
  • Lassa Fever (Lassa Hemorrhagic Fever) - Drug Profiles
    • arevirumab-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-11050 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • favipiravir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GEOLM-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-4500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Lassa fever vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LHF-535 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ML-29 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Lassa Fever - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-193 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects
  • Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 05, 2018: Kineta initiates first-in-human clinical trial of LHF-535 a novel therapy for Lassa fever
      • Aug 20, 2018: Emergent and Profectus receive CEPI contract for Lassa virus vaccine
      • Jun 27, 2018: NIAID Scientists Recommend Favipiravir for Human Trials of Lassa Fever Virus
      • Apr 10, 2018: GeoVax Awarded NIH Fast Track Phase I/II Grant to Advance Lassa Fever Vaccine
      • Oct 24, 2017: Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
      • Jul 24, 2017: GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine
      • Jul 11, 2017: Tulane University awarded $12 million to create Lassa vaccine and treatment
      • Jul 10, 2017: GeoVax Reports Promising Results for Lassa Fever Vaccine
      • May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials
      • Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top